Breakthrough Therapy Designation (FDA)
Definition
An FDA designation that expedites review of drugs showing preliminary clinical evidence of substantial improvement over available therapy for serious conditions. Awarded to psilocybin by USONA and Compass Pathways; does not alter DEA Schedule I status but enables prioritised review of clinical trials.
- Issuing body
- US FDA
- Purpose
- Expedite review of drugs with strong preliminary clinical evidence
- Example recipients
- Psilocybin programs, USONA and Compass Pathways
- Legal effect
- Does not change DEA Schedule I status
Common questions
Does breakthrough therapy designation make a Schedule I drug legal to possess or use?+
No, the designation only expedites the FDA review pathway for a drug's clinical trials; it has no effect on the substance's DEA scheduling, so possession outside an authorised trial remains a federal offence regardless of the designation.
Why does this designation matter for forensic toxicologists?+
It signals that a controlled substance is moving through legitimate clinical trial pipelines, which is relevant context when encountering the substance in a research or trial setting, and it may foreshadow future changes in prescribing or scheduling that toxicology practice will need to track.
Related terms
- 1P-LSD (1-Propionyl-LSD)
- A lysergamide prodrug bearing a propionyl group on the indole N1 position; cleaved in vivo to release LSD. Sold legally in some...
- 5-MeO-DMT
- 5-Methoxy-N,N-dimethyltryptamine; present in Bufo alvarius toad venom at ~15% by weight. Active dose 1-5 mg by inhalation. Schedule I in US since...
- Ayahuasca
- A traditional Amazonian brew combining a DMT-containing plant (Psychotria viridis) with Banisteriopsis caapi containing beta-carboline MAO inhibitors (harmine, harmaline), allowing oral bioavailability...
- Beta-Carboline Alkaloids
- Harmine, harmaline, and tetrahydroharmine; reversible MAO-A inhibitors from Banisteriopsis caapi vine that form the MAOI component of ayahuasca. Detected by HPLC-UV at...
- DMT (N,N-Dimethyltryptamine)
- The simplest tryptamine hallucinogen, MW 188.27 g/mol, orally inactive due to MAO metabolism; active when smoked (25-60 mg) or combined with MAO...
- Ehrlich Reagent
- A presumptive colour test for indole-containing compounds: p-dimethylaminobenzaldehyde in HCl/ethanol. Produces purple-violet with LSD, psilocybin, and all tryptamines. Not specific; many non-drug...
- LSD (Lysergic Acid Diethylamide)
- A potent synthetic hallucinogen derived from lysergic acid, itself from ergot alkaloids of Claviceps purpurea. Active at 50-200 μg. Schedule I in...
- Psilocin
- 4-Hydroxy-N,N-dimethyltryptamine; the active deacylated metabolite of psilocybin responsible for psychedelic effects. Rapidly oxidises in solution, causing the characteristic blue bruising in Psilocybe...
- Psilocybin
- 4-Phosphoryloxy-N,N-dimethyltryptamine; a prodrug found in Psilocybe genus mushrooms. Dephosphorylated in vivo to psilocin (the active form) by alkaline phosphatase. Active at 1-4...